Edition:
United Kingdom

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

3.79EUR
25 Apr 2018
Change (% chg)

€0.03 (+0.80%)
Prev Close
€3.76
Open
€3.75
Day's High
€3.80
Day's Low
€3.75
Volume
116,884
Avg. Vol
203,997
52-wk High
€3.93
52-wk Low
€2.49

Chart for

About

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and... (more)

Overall

Beta: 1.90
Market Cap(Mil.): €294.82
Shares Outstanding(Mil.): 77.58
Dividend: --
Yield (%): --

Financials

  VLS.PA Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -0.15 -- --
ROI: -7.18 -0.73 12.97
ROE: -11.92 -2.77 14.84

BRIEF-Valneva FY Net Loss Narrows To 11.5 Million Euros

* EXPECTS DOUBLE-DIGIT PRODUCT SALES GROWTH TO CONTINUE IN 2018

22 Mar 2018

BRIEF-Valneva Says No Safety Concerns Associated With VLA15 In Any Treatment Group‍​

* NO SAFETY CONCERNS ASSOCIATED WITH VLA15 IN ANY TREATMENT GROUP‍​

19 Mar 2018

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate VLA15

* VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15 Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

19 Mar 2018

BRIEF-Valneva Reports Positive Phase I Interim Results For Its Lyme Vaccine Candidate Vla15

* REG-VALNEVA REPORTS POSITIVE PHASE I INTERIM RESULTS FOR ITS LYME VACCINE CANDIDATE VLA15

19 Mar 2018

BRIEF-Valneva Initiates Phase I Clinical Study Of Vaccine Candidate Against Chikungunya

* REG-VALNEVA INITIATES PHASE I CLINICAL STUDY TO EVALUATE ITS SINGLE-SHOT VACCINE CANDIDATE AGAINST CHIKUNGUNYA

13 Mar 2018

BRIEF-Valneva And Emergent Biosolutions Start Phase 1 Clinical Study To Evaluate Vaccine Candidate Against Zika Virus

* EMERGENT BIOSOLUTIONS AND VALNEVA INITIATE PHASE 1 CLINICAL STUDY TO EVALUATE VACCINE CANDIDATE AGAINST ZIKA VIRUS

26 Feb 2018

BRIEF-Valneva ‍Total Revenues Up At 109.8 Million Euros

* ‍TOTAL REVENUES OF EUR 109.8 MILLION IN 2017 (2016 - EUR 97.9 MILLION)​

15 Feb 2018

BRIEF-Valneva Expands Its Commercial Operations And Establishes US Infrastructure

* REG-VALNEVA EXPANDS ITS COMMERCIAL OPERATIONS AND ESTABLISHES US INFRASTRUCTURE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

30 Nov 2017

BRIEF-Valneva 9M EBITDA increases to 12.3 million euros

* TOTAL REVENUES OF €79.8 MILLION IN FIRST NINE MONTHS 2017 VERSUS TO €70.7 MILLION YEAR AGO‍​

09 Nov 2017

BRIEF-Valneva signs contract with US government

* ANNOUNCED ON TUESDAY SIGNATURE OF $39.6 MILLION IXIARO SUPPLY CONTRACT WITH US GOVERNMENT

08 Nov 2017

Earnings vs. Estimates